Brokerages Expect Genmab A/S (NASDAQ:GMAB) Will Post Quarterly Sales of $300.58 Million

Wall Street analysts predict that Genmab A/S (NASDAQ:GMABGet Rating) will report $300.58 million in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Genmab A/S’s earnings, with the highest sales estimate coming in at $343.39 million and the lowest estimate coming in at $251.40 million. Genmab A/S reported sales of $256.24 million in the same quarter last year, which indicates a positive year-over-year growth rate of 17.3%. The business is expected to report its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Genmab A/S will report full-year sales of $1.77 billion for the current fiscal year, with estimates ranging from $1.70 billion to $1.85 billion. For the next year, analysts forecast that the company will report sales of $2.26 billion, with estimates ranging from $2.12 billion to $2.55 billion. Zacks’ sales averages are an average based on a survey of analysts that that provide coverage for Genmab A/S.

Genmab A/S (NASDAQ:GMABGet Rating) last issued its quarterly earnings data on Wednesday, February 16th. The company reported $0.17 earnings per share for the quarter, topping the consensus estimate of $0.13 by $0.04. The company had revenue of $402.74 million for the quarter, compared to analysts’ expectations of $387.16 million. Genmab A/S had a net margin of 35.58% and a return on equity of 14.23%.

A number of equities research analysts recently weighed in on GMAB shares. Morgan Stanley lowered their target price on shares of Genmab A/S from $33.00 to $30.00 and set an “underweight” rating on the stock in a report on Tuesday, April 12th. HC Wainwright reiterated a “buy” rating and issued a $47.00 price objective on shares of Genmab A/S in a research note on Thursday, March 17th. Guggenheim lowered shares of Genmab A/S from a “buy” rating to a “neutral” rating in a research note on Monday, January 3rd. JPMorgan Chase & Co. decreased their price objective on shares of Genmab A/S from 3,200.00 to 3,100.00 in a research note on Friday, February 25th. Finally, UBS Group upgraded shares of Genmab A/S from a “neutral” rating to a “buy” rating in a research note on Wednesday, March 16th. Four analysts have rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company. According to MarketBeat, Genmab A/S currently has a consensus rating of “Hold” and a consensus price target of $480.86.

Several hedge funds have recently modified their holdings of GMAB. Ellevest Inc. boosted its holdings in Genmab A/S by 21.1% in the 1st quarter. Ellevest Inc. now owns 7,516 shares of the company’s stock worth $272,000 after buying an additional 1,311 shares during the period. Cim LLC boosted its holdings in Genmab A/S by 1.7% in the 1st quarter. Cim LLC now owns 27,994 shares of the company’s stock worth $1,002,000 after buying an additional 465 shares during the period. Veriti Management LLC boosted its holdings in Genmab A/S by 44.7% in the 1st quarter. Veriti Management LLC now owns 10,054 shares of the company’s stock worth $364,000 after buying an additional 3,104 shares during the period. Castleview Partners LLC bought a new position in Genmab A/S in the 4th quarter valued at $211,000. Finally, Sentinel Trust Co. LBA bought a new position in Genmab A/S in the 4th quarter valued at $219,000. Institutional investors own 6.09% of the company’s stock.

GMAB stock opened at $37.48 on Friday. The stock has a market capitalization of $24.64 billion, a PE ratio of 51.34, a price-to-earnings-growth ratio of 1.67 and a beta of 1.04. The company’s 50-day moving average is $34.81 and its 200-day moving average is $37.86. Genmab A/S has a 1 year low of $30.08 and a 1 year high of $49.07.

About Genmab A/S (Get Rating)

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

Featured Stories

Get a free copy of the Zacks research report on Genmab A/S (GMAB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Genmab A/S (NASDAQ:GMAB)

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.